ESR1 and breast cancer: The TNBC subtype lacking expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2), accounts for approximately 15–20% of all BC cases, and is insensitive (unresponsive) to the usual hormone therapies 17.